Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,013 public trials 2,032 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Completed

A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 Trial (PCD)

NCT02244125

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • CHRU Hopital Sud Amiens, France
  • Centre Hospitalier de la côte Basque Bayonne, France
  • Hôpital Avicenne Bobigny, France
  • ICH - Hôpital A. Morvan Brest, France
View all 30 locations
View Trial Details
Completed

A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)

NCT02588651

Conditions
Adult T-Cell Leukemia/Lymphoma, Angioimmunoblastic T-cell Lymphoma, Enteropathy Associated T-cell Lymphoma, +22 more
Locations
  • Wayne State University, Karmanos Cancer Institute Detroit, Michigan, United States
  • Hackensack University Medical Center Hackensack, New Jersey, United States
  • University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center Cleveland, Ohio, United States
  • Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center Cleveland, Ohio, United States
View Trial Details
Completed

Real-life Efficacy and Toxicity of Brentuximab-Vedotin Associated With Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma (HL-R2-B2)

NCT07145125

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Hodgkin Disease, +11 more
Locations
  • CH de la Côte Basque, service Hématologie Clinique Bayonne, France
  • CHU de Bordeaux, service Hématologie Clinique et Thérapie cellulaire Bordeaux, France
  • CHU de Caen, service Hématologie Clinique Caen, France
  • Institut Paoli Calmettes, service Hématologie Clinique Marseille, France
View Trial Details
Completed

Study of Zanubrutinib in Japanese Participants With B-Cell Malignancies

NCT04172246

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +28 more
Locations
  • Nagoya University Hospital Nagoya, Aichi-ken, Japan
  • Toyohashi Municipal Hospital Toyohashishi, Aichi-ken, Japan
  • Chiba Cancer Center Chiba, Japan
  • Matsuyama Red Cross Hospital Matsuyama, Ehime, Japan
View all 15 locations
View Trial Details
Completed

Veliparib and Temozolomide in Treating Patients With Acute Leukemia

NCT01139970

Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, +45 more
Locations
  • University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
  • University of Maryland/Greenebaum Cancer Center Baltimore, Maryland, United States
  • Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States
View Trial Details
Completed

High Dose Carfilzomib for Newly Diagnosed Myeloma

NCT02937571

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Memorial Sloan Kettering Cancer Center Basking Ridge, New Jersey, United States
  • Memorial Sloan Kettering Monmouth Middletown, New Jersey, United States
  • Memorial Sloan Kettering Bergen Montvale, New Jersey, United States
  • Memorial Sloan Kettering Cancer Center @ Suffolk Commack, New York, United States
View Trial Details

Related conditions